The research on regenerative therapies such as gene therapy to treat sickle cell diseases is highly promising. Hence, many pharmaceutical vendors are researching these therapies. These advances in research will contribute significantly to drive the Global Sickle cell disease treatment market. Sickle cell anaemia is a disorder of the Red Blood Cells (RBC) is sickle cell anaemia which is an inherited disease. RBC’s have a short life span in this disease thus healthy cells does not receive adequate amount of oxygen to the organs. In normal conditions, the red blood cells move easily through the blood vessels and are flexible round in shape. Whereas In disease like sickle cell anemia the red blood cells become rigid and sticky and are sickle-shaped. Thus, RBC block the flow of oxygen and blood to the other parts of the body by getting stuck in the blood vessels. Mutation in the gene causes sickle cell anemia. Currently available treatments for sickle cell disease (SCD) provide a symptomatic relief and palliative care. The treatment includes blood transfusions, bone marrow transplant, and pharmacotherapy. Although bone marrow transplant is the only curative treatment, it is recommended only to a small percentage of patients. The disease has only two approved products hydroxyurea and Endari in the market.
This growth is primarily driven by High prevalence of Sickle cell disease patients in recent years, Investments being done by the Government and Regulatory bodies in R & D to find new therapeutic drugs and treatment for the disease and Increasing product pipeline for sickle cell disease..
Globally, a noticeable market trend is evident Favorable reimbursement policies attributed to the sickle cell disease
. The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as AddMedica (France), Bristol-Mayers Squibb (United States), Emmaus Life Sciences, Inc. (United States), Novartis (Switzerland), Pfizer (United States), Baxter International Inc. (United States), Bluebird bio, Inc. (United States), Global Blood Therapeutics Inc. (United States), Sangamo Therapeutics, Inc. (United States) and Acceleron Pharma, Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.
Key Developments in the Market:
In January 2019, FDA has granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD). and In December 2018, New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumaba once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated for the treatment of sickle cell disease (SCD and it shows a greater reductions of Vaso-occlusive crises (VOCs) in patients who were adherent to the treatment protocol.
In December 2018, Foundation for Sickle cell Disease Research (FSCDR) received first sickle cell hospital in Miami –Dade country. The sickle cell hospital is to expand on the services offered at FSCDR’s flagship center and includes wraparound services to improve the overall quality of life for an individual with sickle cell disease.
- High prevalence of Sickle cell disease patients in recent years
- Investments being done by the Government and Regulatory bodies in R & D to find new therapeutic drugs and treatment for the disease
- Increasing product pipeline for sickle cell disease.
- Favorable reimbursement policies attributed to the sickle cell disease
- Unavailability of drugs in rural areas in countries like India
- Lack of proper healthcare Infrastructure in MEA countries
- High-cost treatment for Sickle cell disease
Increasing activities in R & D and accessibility to developed healthcare infrastructure.
Lack of approved therapies and drugs for Sickle cell disease and Treatment of the disease is a complex procedure.
AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.
Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
Against this Challenging Backdrop, Sickle Cell Disease Treatment Study Sheds Light on
The Sickle Cell Disease Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Sickle Cell Disease Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
Where Sickle Cell Disease Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.